Recursion Pharmaceuticals is maintained at a "Hold" rating. Read the latest analysis here on RXRX stock.
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.
RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.05, representing a +2.02% change from its previous close.
Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
This is the newest page. Registered accounts read further back.